| P50 | author | Richard Adebayo Adegbola | Q75114791 |
| P2093 | author name string | Steffen Glismann | |
| | Ruprecht Schmidt-Ott | |
| | Karin Hardt | |
| | François P Meurice | |
| P2860 | cites work | What led to the Nigerian boycott of the polio vaccination campaign? | Q21144676 |
| | Industry sponsorship and research outcome | Q24202591 |
| | Pharmaceutical industry sponsorship and research outcome and quality: systematic review | Q24673248 |
| | The Vaccine Safety Datalink: a model for monitoring immunization safety | Q27010367 |
| | RETRACTED: Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children | Q28264479 |
| | The clinician's guide to the anti-vaccinationists' galaxy | Q28264526 |
| | Controversies in vaccine mandates. | Q30386687 |
| | Determinants of adults' intention to vaccinate against pandemic swine flu. | Q30398302 |
| | About courageous scientists, responsible policy makers, bridge-builders and preparedness for the next influenza pandemic | Q30426075 |
| | Communicating with parents about vaccination: a framework for health professionals. | Q31098840 |
| | Global immunization: status, progress, challenges and future | Q33510451 |
| | Relationships between the pharmaceutical industry and patients' organisations | Q33815160 |
| | Anti-vaccine activists, Web 2.0, and the postmodern paradigm--an overview of tactics and tropes used online by the anti-vaccination movement | Q34029837 |
| | Impact of anti-vaccine movements on pertussis control: the untold story | Q34066899 |
| | Vaccine herd effect | Q34186752 |
| | Addressing the vaccine confidence gap. | Q34191703 |
| | Effects of a web based decision aid on parental attitudes to MMR vaccination: a before and after study. | Q34276229 |
| | A population-based cohort study of undervaccination in 8 managed care organizations across the United States. | Q34323703 |
| | Strengthening the U.S. vaccine and immunization enterprise: the role of the National Vaccine Advisory Committee | Q34405697 |
| | Reasons for receiving or not receiving HPV vaccination in primary schoolgirls in Tanzania: a case control study | Q34463429 |
| | Evidence b(i)ased medicine--selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications | Q34534086 |
| | Measles still spreads in Europe: who is responsible for the failure to vaccinate? | Q34643702 |
| | Historical comparisons of morbidity and mortality for vaccine-preventable diseases in the United States | Q34655381 |
| | Parents' source of vaccine information and impact on vaccine attitudes, beliefs, and nonmedical exemptions | Q36311179 |
| | Ensuring the quality, potency and safety of vaccines during preclinical development | Q36350572 |
| | Key opinion leaders: independent experts or drug representatives in disguise? | Q36728956 |
| | New challenges in assuring vaccine quality | Q36921456 |
| | Social and behavioral science in HIV vaccine trials: a gap assessment of the literature | Q37386288 |
| | The need for new vaccines | Q37652534 |
| | Modelling the influence of human behaviour on the spread of infectious diseases: a review | Q37760973 |
| | An overview on the implementation of HPV vaccination in Europe | Q37829845 |
| | Food and Drug Administration regulation and evaluation of vaccines | Q37866532 |
| | Who gets measles in Europe? | Q37888353 |
| | Intussusception risk and health benefits of rotavirus vaccination in Mexico and Brazil | Q37889979 |
| | Toward interactive, Internet-based decision aid for vaccination decisions: better information alone is not enough. | Q37974808 |
| | Remaining issues and challenges for rotavirus vaccine in preventing global childhood diarrheal morbidity and mortality | Q37981766 |
| | Healthcare workers role in keeping MMR vaccination uptake high in Europe: a review of evidence | Q38025922 |
| | Considerations for setting the specifications of vaccines | Q38028995 |
| | Current status and future directions of post-marketing vaccine safety monitoring with focus on USA and Europe | Q38035703 |
| | Meeting the need for advocacy, social mobilisation and communication in the introduction of three new vaccines in South Africa - successes and challenges | Q38039621 |
| | Addressing public questioning and concerns about vaccination in South Africa: a guide for healthcare workers | Q38039623 |
| | Financing vaccinations - the South African experience | Q38039625 |
| | Cost-effectiveness and economic benefits of vaccines in low- and middle-income countries: a systematic review | Q38059027 |
| | Human papillomavirus vaccine introduction--the first five years | Q38064062 |
| | Upgrading public health programs for human papillomavirus prevention and control is possible in low- and middle-income countries | Q38064065 |
| | Implementation of human papillomavirus immunization in the developing world | Q38064066 |
| | Capacity for a global vaccine safety system: the perspective of national regulatory authorities. | Q38416020 |
| | Multiple sclerosis and hepatitis B vaccine? | Q39042048 |
| | Opportunities and challenges of Web 2.0 for vaccination decisions. | Q39648121 |
| | Disparities in influenza vaccination coverage rates by target group in five European countries: trends over seven consecutive seasons. | Q39945576 |
| | Progress toward poliomyelitis eradication - Nigeria, January 2011-September 2012. | Q42287359 |
| | The new BMJ policy on sharing data from drug and device trials | Q42677549 |
| | No more free lunches | Q42783241 |
| | Medical journals and pharmaceutical companies: uneasy bedfellows. | Q42783290 |
| | Drug industry's new code criticised for lacking teeth | Q43107738 |
| | Progress in the introduction of rotavirus vaccine--Latin America and the Caribbean, 2006-2010. | Q44313509 |
| | Clinical trial data for all drugs in current use. | Q44483480 |
| | Parental response to the introduction of a vaccine against human papilloma virus | Q44672461 |
| | Advisory Committee on Immunization Practices (ACIP) recommended immunization schedule for adults aged 19 years and older--United States, 2013. | Q44831801 |
| | Effect of rotavirus vaccine on diarrhea mortality in different socioeconomic regions of Mexico | Q44915493 |
| | Risk of intussusception following administration of a pentavalent rotavirus vaccine in US infants | Q45306314 |
| | Assessment of relevant cultural considerations is essential for the success of a vaccine. | Q47302020 |
| | Monitoring of progress in the establishment and strengthening of national immunization technical advisory groups | Q47874029 |
| | Determinants of Trust in Industry, Government, and Citizen's Groups in Japan | Q47932621 |
| | Estimated economic benefits during the 'decade of vaccines' include treatment savings, gains in labor productivity | Q47981876 |
| | Andrew Witty: the acceptable face of big pharma? Interviewed by Rebecca Coombes | Q48401322 |
| | Global routine vaccination coverage, 2010. | Q50593509 |
| | Postmarketing surveillance of intussusception following mass introduction of the attenuated human rotavirus vaccine in Mexico. | Q50936943 |
| | Clinical trial registration: a statement from the International Committee of Medical Journal Editors. | Q55038991 |
| | Intussusception following rotavirus vaccine administration: Post-marketing surveillance in the National Immunization Program in Australia | Q56638996 |
| | The Vaccine Adverse Event Reporting System (VAERS) | Q64135436 |
| | Withdrawal of rotavirus vaccine recommendation | Q73217916 |
| | [Hepatitis B vaccination and the risk of multiple sclerosis: case-control studies] | Q77654004 |
| | Intussusception among recipients of rotavirus vaccine--United States, 1998-1999 | Q78066953 |
| | Real-time vaccine safety surveillance for the early detection of adverse events | Q81382227 |
| | Is the relationship between pharma and medical education on the rocks? | Q81784864 |
| | Measles is still a cause for concern in Europe | Q81923997 |
| | Global routine vaccination coverage, 2010 | Q82737567 |
| | Global Advisory Committee on Vaccine Safety,3-4 December 2009 | Q82878095 |
| | Postmarketing evaluation of the short-term safety of the pentavalent rotavirus vaccine | Q82980107 |
| | Human papillomavirus vaccines. WHO position paper | Q83635819 |
| | Dr. Jekyll or Mr. Hyde? (How) the Internet influences vaccination decisions: recent evidence and tentative guidelines for online vaccine communication | Q83800630 |
| | Confidence about vaccines in the United States: understanding parents' perceptions | Q84305243 |
| | A call to action for the new decade of vaccines | Q84336182 |
| | ECDC in collaboration with the VAESCO consortium to develop a complementary tool for vaccine safety monitoring in Europe | Q84675474 |
| | Risk perception, risk management and safety assessment: what can governments do to increase public confidence in their vaccine system? | Q85083789 |
| | Toward clinical transparency | Q85389281 |
| | Improving R&D productivity of pharmaceutical companies through public-private partnership: experiences from the Innovative Medicines Initiative | Q85393585 |
| | Rotavirus vaccines. WHO position paper – January 2013 | Q86171140 |
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 204-24 | |
| P577 | publication date | 2013-06-24 | |
| P1433 | published in | Vaccines | Q27725508 |
| P1476 | title | Sustaining Vaccine Confidence in the 21st Century | |
| P478 | volume | 1 | |